After norovirus vaccine's trial failure, HilleVax lays off 40% of staff
Boston biotech HilleVax said Wednesday that it will let go about 41 employees, or roughly 40% of its staff, after its lead vaccine failed a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
